Factor V Leiden homozygous mutation: Recurrent venous thromboembolism during periods of discontinuation of anticoagulant therapy

Authors

DOI:

https://doi.org/10.17532/jhsci.2021.1283

Keywords:

Venous thromboembolism, homozygous Factor V Leiden mutation, anticoagulant therapy

Abstract

Venous thromboembolism (VTE), also known as deep vein thrombosis and pulmonary thromboembolism, is a medical condition that has a high incidence and a multifactorial pathogenesis. One of the causes is a mutation of the Factor V Leiden (FVL), which is the most common inherited thrombotic disorder. A mutation inherited from both parents is found in about 0.05-0.5% of cases, making our case more medically interesting. We presented the case of a young male patient with recurrent VTE and few risk factors who was admitted to the hospital 4 times with VTE symptoms over a 5-year period. In the background, there was a homozygous FVL mutation and improper use of anticoagulant therapy. We examined the medical data, diagnostics, therapy, and precautions that were and are required.

Downloads

Download data is not yet available.

Downloads

Published

2021-09-16

How to Cite

Šahinović, S., Huskić, V., & Kauković, A. (2021). Factor V Leiden homozygous mutation: Recurrent venous thromboembolism during periods of discontinuation of anticoagulant therapy. Journal of Health Sciences, 11(2), 137–141. https://doi.org/10.17532/jhsci.2021.1283

Issue

Section

Case reports